Glimepiride

WorldBrand briefing

AI supplement

Original synthesis to sit alongside the encyclopedia article below. Not part of Wikipedia; verify facts on Wikipedia when precision matters.

Glimepiride (Chinese name 格列美脲) is a long-acting third-generation sulfonylurea oral antihyperglycemic medication indicated to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. It works primarily by blocking ATP-sensitive potassium channels on pancreatic beta cells to stimulate endogenous insulin release, with additional mild extra-pancreatic effects that increase peripheral tissue glucose uptake. It is not approved for treatment of type 1 diabetes or diabetic ketoacidosis.

Key moments

1970First chemical synthesis of glimepiride completed, followed by decades of preclinical and clinical safety and efficacy trials
1995Receives official FDA approval for clinical use in the U.S., originally marketed under the brand name Amaryl
2000sIncluded on the WHO core List of Essential Medicines as a recommended first-line affordable antidiabetic agent
2023First fixed-dose combination formulations pairing glimepiride with other antidiabetic drugs (e.g. dapagliflozin) gain regulatory approval in multiple regions to simplify patient dosing

Distinct clinical advantages over older sulfonylurea alternatives

Unlike older first and second generation sulfonylurea medications that require multiple daily doses, glimepiride's once-daily long half-life reduces patient burden and the risk of missed doses. It also carries a lower documented risk of severe, prolonged hypoglycemia relative to counterparts like glyburide, making it a more suitable option for elderly patients and those with mild renal impairment who require cautious glycemic management.

Public health accessibility and cost value

Years after its original composition patent expired, generic glimepiride is mass-produced by hundreds of drug manufacturers globally at very low cost. It remains one of the most accessible long-term type 2 diabetes management options, particularly for low and middle-income national healthcare systems that cannot afford widespread deployment of far more expensive newer GLP-1 agonist medications. It is a core budget-friendly staple of public diabetes care programs across most emerging economies.

Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes.[1] It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. It is taken by mouth, reaching a peak effect within three hours and lasting for about a day.

Common side effects include headache, nausea, and dizziness. Serious side effects may include low blood sugar. Use during pregnancy and breastfeeding is not recommended.[2] It works predominantly by increasing the amount of insulin released from the pancreas.[3] It is classified as a second-generation sulfonylurea.[4]

Glimepiride

WorldBrand briefing

Distinct clinical advantages over older sulfonylurea alternatives

Public health accessibility and cost value

Medical uses

Contraindications

Adverse effects

Interactions

Mechanism of action

Pharmacokinetics

References